Huge reversal today
All my statements are my opinion after performing extensive due diligence. No statement of mine should be taken as investment advice or as an attempt to solicit a buy or sell of a security. Invest wisely.
Recent PRTA News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/10/2026 11:21:36 PM
- Prothena Announces Leadership Team Updates • Business Wire • 04/10/2026 08:05:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/27/2026 08:20:23 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/27/2026 08:13:54 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/27/2026 08:03:27 PM
- Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026 • Business Wire • 03/21/2026 08:05:00 PM
- Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy • Business Wire • 03/09/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:51:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:51:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:50:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:50:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2026 09:45:57 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 02/27/2026 09:41:52 PM
- Prothena Announces up to $100 Million Share Repurchase Plan • Business Wire • 02/27/2026 09:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2026 09:04:46 PM
- Form POSASR - Post-effective Amendment to an automatic shelf registration statement • Edgar (US Regulatory) • 02/27/2026 09:01:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/19/2026 09:07:15 PM
- Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights • Business Wire • 02/19/2026 09:05:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/13/2026 09:16:32 PM
- Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 • Business Wire • 02/12/2026 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2025 09:26:08 PM
- Prothena Announces Board of Directors Update • Business Wire • 12/12/2025 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/19/2025 09:30:57 PM
- Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025 • Business Wire • 11/19/2025 09:05:00 PM
